Rating Change
Barclays reiterated its Overweight rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) on October 07, 2026.
reiterateNASDAQ:BBIO
Barclays Reiterates Overweight Rating on BridgeBio Pharma, Inc. (BBIO)
Barclays reiterated its Overweight rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) on October 07, 2026.
At publication ·
What changed
BridgeBio Pharma, Inc. (NASDAQ:BBIO) · reiterate
- Firm
- Barclays
- Rating
- Overweight to Overweight
- Price at event
- $66.71
- Market capitalization
- $14.1B
At a glance
Key takeaways
- Barclays reiterated an Overweight rating on BridgeBio Pharma (BBIO) on October 7, 2026, with the stock trading at $66.71 and a market cap of $14.1 billion.
Market Context
BridgeBio Pharma, Inc. operates in the Healthcare sector. The stock currently trades at $66.71 with a market capitalization of $14.1B. The stock has gained 25.1% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for BridgeBio Pharma, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for BridgeBio Pharma, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 07, 2026 | Barclays | Overweight | N/A |
| Sep 10, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 02, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 01, 2026 | Mizuho | Outperform | N/A |
| Aug 12, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View BBIO Stock Page
Frequently Asked Questions
What does the Overweight rating mean for BBIO?
A rating of Overweight from Barclays reflects the analyst's outlook on BridgeBio Pharma, Inc. (NASDAQ:BBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BBIO forecast page.
